TAK — Takeda Pharmaceutical Share News
0.000.00%
Last trade - 00:00- $66.14bn
- $92.15bn
- ¥5tn
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Brief: U.S. FDA Accepts Takeda's Application For Intravenous Entyvio® (Vedolizumab) In Pediatric Ulcerative Colitis And Crohn's Disease
Recorded 402.5 Billion Yen Additional Provision For Legal Proceedings After U.S. Jury Verdict In Antitrust Litigation
Table: Takeda Pharma -2025/26 group results (IFRS)
Table: Takeda Pharma -2025/26 parent results
Notice Concerning Withdrawal Of Shelf Registration Statement And Filing Of New Shelf Registration Statement In Japan
Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
Brief: Takeda Pharmaceutical - Currently Assessing Amount Of Provision To Be Recognized In Group Earnings For FY Ended March 31
Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds (updated)
Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds
US jury to decide if Takeda delayed generic constipation drug
Bain-backed Tanabe Pharma targets three new drug launches a year in Japan
Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring (updated)
Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring
US FDA approves BeOne's drug for a type of blood cancer (updated)
Table: Takeda Pharma -2025/26 parent results
Table: Takeda Pharma -2025/26 group results (IFRS)
Morning Bid Europe: Locked in a stalemate with Iran, Trump heads to China
Brief: British Columbia Reimburses Revestive® (Teduglutide For Injection) For The Treatment Of Short Bowel Syndrome